Topics
Glioblastoma | Etiopathogenesis | Resistance
Home > Publications > Topics > Glioblastoma > Etiopathogenesis > Resistance
Piccirillo SG, Spiteri I, Sottoriva A, Touloumis A, Ber S, Price
SJ, Heywood R, Francis NJ, Howarth KD, Collins VP, Venkitaraman
AR, Curtis C, Marioni JC, Tavaré S, Watts C.
Contributions
to drug resistance in glioblastoma derived from malignant cells in
the sub-ependymal zone.
Cancer
Res. 2014 Nov 18;75(1):194-202. doi:
10.1158/0008-5472.CAN-13-3131. PMID:
25406193. Laboratory investigation. ˍ
Chang
C, Chavarro VS, Gerstl JVE, Blitz SE, Spanehl L, Dubinski D,
Valdes PA, Tran LN, Gupta S, Esposito L, Mazzetti D, Gessler FA,
Arnaout O, Smith TR, Friedman GK, Peruzzi P, Bernstock JD.
Recurrent
Glioblastoma-Molecular Underpinnings and Evolving Treatment
Paradigms.
Int
J Mol Sci.
2024 Jun 19;25(12):6733. doi:
10.3390/ijms25126733. PMID:
38928445.
Review. ˍ
Palizkaran
Yazdi M, Barjasteh A, Moghbeli M.
MicroRNAs
as the pivotal regulators of Temozolomide resistance in
glioblastoma.
Mol
Brain.
2024 Jul 2;17(1):42. doi:
10.1186/s13041-024-01113-6. PMID:
38956588. Review. ˍ
Sherman JH, Bobak A, Arsiwala T, Lockman P, Aulakh S.
Targeting
drug resistance in glioblastoma (Review).
Int
J Oncol. 2024 Jul 9;65(2):80. doi:
10.3892/ijo.2024.5668. PMID:
38994761.
Review. ˍ
Pathikonda S, Amirmahani F, Mathew D, Muthukrishnan SD.
Histone
acetyltransferases as promising therapeutic targets in
glioblastoma resistance.
Cancer
Lett. 2024 Sep 24;604:217269. doi:
10.1016/j.canlet.2024.217269. PMID:
39326554. Review. ˍ
Alshammari QA, Alshammari SO, Alshammari A, Alfarhan M, Baali FH.
Unraveling the mechanisms of
glioblastoma's resistance: investigating the influence of tumor
suppressor p53 and non-coding RNAs.
Naunyn
Schmiedebergs Arch Pharmacol. 2024 Oct 30. doi:
10.1007/s00210-024-03564-z. PMID:
39476245. Review˰ ˍ
Kricha A, Bouchmaa N, Ben Mkaddem S, Abbaoui A, Ben Mrid R, El
Fatimy R.
Glioblastoma-associated
macrophages: A key target in overcoming glioblastoma therapeutic
resistance.
Cytokine
Growth Factor Rev. 2024 Oct 31:S1359-6101(24)00088-1.
doi:
10.1016/j.cytogfr.2024.10.009. PMID:
39510901. Review. ˍ
Sørensen MD, Olsen RFS, Burton M, Kavan S, Petterson SA,
Thomassen M, Kruse TA, Meyer M, Kristensen BW.
Microglia
induce an interferon-stimulated gene expression profile in
glioblastoma and increase glioblastoma resistance to
temozolomide.
Neuropathol
Appl Neurobiol. 2024 Nov 18;50(6):e13016. doi:
10.1111/nan.13016. PMID:
39558550. Laboratory investigation. ˍ
Wu H, Gao W, Chen P, Wei Y, Zhao H, Wang F.
Research
progress of drug resistance mechanism of temozolomide in the
treatment of glioblastoma.
Heliyon.
2024 Oct 30;10(21):e39984. doi:
10.1016/j.heliyon.2024.e39984. PMID:
39568843. Review. ˍ
Bou-Gharios J, Noël G, Burckel H.
The
neglected burden of chronic hypoxia on the resistance of
glioblastoma multiforme to first-line therapies.
BMC
Biol. 2024 Nov 28;22(1):278. doi:
10.1186/s12915-024-02075-w. PMID:
39609830. Review. ˍ
Nomogram
Xue J, Zhang J, Zhu J.
Unraveling
molecular signatures and prognostic biomarkers in glioblastoma: a
comprehensive study on treatment resistance and personalized
strategies.
Discov
Oncol. 2024 Dec 4;15(1):743. doi:
10.1007/s12672-024-01649-y. PMID:
39630160. Observational study. ˍ